Operating And Business Equipment Operating And Business Equipment [Member] Operating And Business Equipment Biotheus (previously Simba Merger Sub) Biotheus (previously Simba Merger Sub) [Member] Biotheus (previously Simba Merger Sub) Disclosure of contingent liabilities [line items] Disclosure of contingent liabilities [line items] Interest expenses from effective interest method and other interest expenses Interest expense Purchase of property, plant and equipment Purchase of property, plant and equipment, classified as investing activities Sale Of Stock [Domain] Sale Of Stock [Domain] Sale Of Stock [Domain] Average price paid per ADS (in dollar per share and euro per share) Share Repurchase Program, Average Price Per American depositary Share (ADS) Share Repurchase Program, Average Price Per American depositary Share (ADS) Wages and salaries Wages and salaries Entity File Number Entity File Number Non-current liabilities Non-current liabilities recognised as of acquisition date Disclosure of detailed information about business combination [line items] Disclosure of detailed information about business combination [line items] BioNTech Europe GmbH BioNTech Europe GmbH [Member] BioNTech Europe GmbH Deferred taxes Deferred tax expense (income) Other gains Other finance income Summary of Useful Lives Applied to the Group's Intangible Assets Disclosure of detailed information about intangible assets [text block] Levels of fair value hierarchy [domain] Levels of fair value hierarchy [domain] Non-current obligations under lease contracts Noncurrent Obligations Under Lease Contracts [Member] Noncurrent Obligations Under Lease Contracts Equity-Settled Share-Based Payment Arrangements Equity-Settled Share-Based Payment Arrangements [Member] Equity-Settled Share-Based Payment Arrangements Impairment loss recognised in profit or loss, right-of-use assets Impairment loss recognised in profit or loss, right-of-use assets Additions from business combinations Increase (Decrease) In Contract Liabilities From Business Combinations Increase (Decrease) In Contract Liabilities From Business Combinations Deferred tax liabilities recognised as of acquisition date Deferred tax liabilities recognised as of acquisition date Summary of Changes in Liabilities Arising from Financing Activities Disclosure of reconciliation of liabilities arising from financing activities [text block] BioNTech Diagnostics GmbH BioNTech Diagnostics GmbH [Member] BioNTech Diagnostics GmbH Payment terms in contracts with customers Description of significant payment terms in contracts with customers Other effects Other tax effects for reconciliation between accounting profit and tax expense (income) Net gain / (loss) on equity instruments designated at fair value through other comprehensive income Other comprehensive income, net of tax, gains (losses) from investments in equity instruments Total finance result Finance income (cost) Finance income (cost) Summary of Right-of-Use Assets within Consolidated Statements of Financial Position Disclosure of quantitative information about right-of-use assets [text block] Fair Value Measurement Description of accounting policy for fair value measurement [text block] thereof allocated and un-vested (in shares) Number Of Share Options Allocated And Unvested In Share-Based Payment Arrangement Number Of Share Options Allocated And Unvested In Share-Based Payment Arrangement Cash outflow to tax authority Cash Outflow To Tax Authority Cash Outflow To Tax Authority Number shares vested (in shares) Number of option rights vested (in shares) Number of other equity instruments exercised or vested in share-based payment arrangement Share Repurchase Program, Tranche Two Share Repurchase Program, Tranche Two [Member] Share Repurchase Program, Tranche Two Other intangible assets Beginning balance Ending balance Intangible assets and goodwill Statement of comprehensive income [abstract] Statement of changes in equity [line items] Statement of changes in equity [line items] Non-current Non-Currnet Contract Assets [Roll Forward] Non-Currnet Contract Assets CureVac Corporate Services GmbH CureVac Corporate Services GmbH [Member] CureVac Corporate Services GmbH Additions from business combinations Increase (Decrease) In Non-Current Contract Liabilities From Business Combinations Increase (Decrease) In Non-Current Contract Liabilities From Business Combinations Increase (decrease) in intangible assets Increase (decrease) in intangible assets and goodwill Additions Increase (Decrease) In Current Contract Assets Increase (Decrease) In Current Contract Assets Liabilities from share-based payment transactions, current Liabilities From Share-Based Payment Transactions, Current Liabilities From Share-Based Payment Transactions, Current BioNTech Research and Development, Inc. BioNTech Research and Development, Inc. [Member] BioNTech Research and Development, Inc. Additions from business combinations Acquisitions through business combinations, intangible assets and goodwill Production Facilities [Member] Production Facilities [Member] Production Facilities Currency differences Increase (decrease) through net exchange differences, intangible assets and goodwill Statement of financial position [abstract] Total other operating result Other operating income (expense) Purchase of intangible assets Purchase Of Intangible Assets And Right-Of-Use Assets, Classified As Investing Activities Purchase Of Intangible Assets And Right-Of-Use Assets, Classified As Investing Activities Cover [Abstract] Maximum Maximum [Member] Loans and borrowings Interest Bearing Loans And Borrowings Interest Bearing Loans And Borrowings Provisions Description of accounting policy for provisions [text block] Settlement Date April 3 2025 Settlement Date April 3 2025 [Member] Settlement Date April 3 2025 Estimated Allocation Date Seven PSUs Estimated Allocation Date Seven PSUs [Member] Estimated Allocation Date Seven PSUs Classes of intangible assets other than goodwill [axis] Classes of intangible assets other than goodwill [axis] Federal tax credits Accumulated Tax Losses In Federal Tax Credits Accumulated Tax Losses In Federal Tax Credits Entity Shell Company Entity Shell Company Deferred tax liabilities have not been recognized Temporary differences associated with investments in subsidiaries, branches and associates and interests in joint arrangements for which deferred tax liabilities have not been recognised Financing activities Cash flows from (used in) financing activities [abstract] Classes of liabilities Classes of liabilities [domain] Maximum cash payment Maximum Cash Payment In Share-Based Payment Arrangement Maximum Cash Payment In Share-Based Payment Arrangement Comprehensive income / (loss), net of tax Comprehensive income Share based payment arrangement incentive value Share Based Payment Arrangement Incentive Value Share Based Payment Arrangement Incentive Value Other Customers Other Customers [Member] Other Customers Unfinished goods Current work in progress Current liabilities Current liabilities recognised as of acquisition date CureVac Swiss AG CureVac Swiss AG [Member] CureVac Swiss AG Document Fiscal Period Focus Document Fiscal Period Focus Sean Marett Sean Marett [Member] Sean Marett Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [line items] Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [line items] Employee Stock Ownership Plan Cash Settled Employee Stock Ownership Plan Cash Settled [Member] Employee Stock Ownership Plan Cash Settled Total assets Assets Expense / (Income) arising from cash-settled share-based payment arrangements Expense from cash-settled share-based payment transactions As of January 1 As of December 31 Contract assets Other financial liabilities Other financial liabilities Assets Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [abstract] Taxes Description of accounting policy for income tax [text block] Other financial liabilities Other Financial Liabilities [Member] Other Financial Liabilities Cost of sales Cost of sales [member] Associates [domain] Associates [domain] Group Information Disclosure of composition of group [text block] Number of other equity instruments outstanding in share-based payment arrangement (in shares) Beginning balance (in shares) Ending balance (in shares) Number of other equity instruments outstanding in share-based payment arrangement Trading Symbol Trading Symbol Sales and marketing expenses Sales And Marketing Expense [Member] Sales And Marketing Expense AC Amortized Cost [Member] Amortized Cost Goods and services transferred at a point in time Goods or services transferred at point in time [member] Entity Address, City or Town Entity Address, City or Town Foreign exchange forward contracts Forward contract [member] Share capital Issued capital [member] Other reserves Other reserves [member] Summary of Compensation of Key Management Personnel Disclosure of information about key management personnel [text block] Other Provisions, Contingent Liabilities And Contingent Assets [Abstract] Other Provisions, Contingent Liabilities And Contingent Assets [Abstract] Other Provisions, Contingent Liabilities And Contingent Assets [Abstract] Cash flows Increase (decrease) through financing cash flows, liabilities arising from financing activities Biotheus Inc. Biotheus Inc. [Member] Biotheus Inc. Tax rate effect Tax rate effect from change in tax rate Equity method investment, ownership (as a percent) Equity Method Investments, Ownership Percentage Equity Method Investments, Ownership Percentage Disclosure of quantitative information about right-of-use assets [table] Disclosure of quantitative information about right-of-use assets [table] Entity Emerging Growth Company Entity Emerging Growth Company Biotheus Founder SBP Program Biotheus Founder SBP Program [Member] Biotheus Founder SBP Program Effects in connection with pre-existing relationships Previously-held Non-listed Equity Investment Previously-held Non-listed Equity Investment CureVac Manufacturing GmbH CureVac Manufacturing GmbH [Member] CureVac Manufacturing GmbH Other non-financial assets Total non-current Other non-current non-financial assets Disposals Disposals, property, plant and equipment Expected tax credit Tax expense (income) at applicable tax rate Phantom shares awarded (in shares) Key Management Personnel Compensation, Phantom Shares Awarded Key Management Personnel Compensation, Phantom Shares Awarded Business Combinations and Goodwill Description of accounting policy for business combinations and goodwill [text block] Assets Assets [abstract] List Of Accounting Policies [Abstract] List Of Accounting Policies [Abstract] List Of Accounting Policies [Abstract] Right-of-use assets Right-of-use assets [member] reSano GmbH reSano GmbH [Member] reSano GmbH Non-current Non-Current Contract Liabilities [Roll Forward] Non-Current Contract Liabilities BioNTech Idar-Oberstein Services GmbH BioNTech Idar-Oberstein Services GmbH [Member] BioNTech Idar-Oberstein Services GmbH thereof fair value of shares from first and second offer period transferred Purchase Price, Acquisition-Date Fair Value, First and Second Offering Period Purchase Price, Acquisition-Date Fair Value, First and Second Offering Period Weighted average share price (in euros per share) Weighted average share price, share options granted Current assets Current assets [abstract] CureVac CureVac [Member] CureVac Entity Address, Postal Zip Code Entity Address, Postal Zip Code Biopharma BioNTech Israel Ltd. Biopharma BioNTech Israel Ltd. [Member] Biopharma BioNTech Israel Ltd. Non-current assets Non-current assets [abstract] Phantom Share Options Phantom Share Options [Member] Phantom Share Options Disclosure of reserves within equity [table] Disclosure of reserves within equity [table] Sale Of Stock [Axis] Sale Of Stock [Axis] Sale Of Stock General and administrative expenses General and administrative expenses General and administrative expense Cash and cash equivalents Cash and cash equivalents recognised as of acquisition date Income Tax Disclosure of income tax [text block] Non tax-effective share-based payment expenses Non-Recognition Of Tax Effect On Share-Based Payment Expenses Non-Recognition Of Tax Effect On Share-Based Payment Expenses Revenue from Contracts with Customers Description of accounting policy for recognition of revenue [text block] Transaction costs related to issuance of share capital Payments for share issue costs Increase (decrease) through other changes, right-of-use assets Increase (decrease) through other changes, right-of-use assets Insurance Obligation And Service Contracts Insurance Obligation And Service Contracts [Member] Insurance Obligation And Service Contracts -5 % Negative Five Percentage Change In Foreign Exchange Rate [Member] Negative Five Percentage Change In Foreign Exchange Rate Summary of Number and Weighted-Average Exercise Price of Share Options Disclosure of number and weighted average exercise prices of share options [text block] Software Computer software [member] Summary of Employee Benefits Expense Disclosure Of Detailed Information About Employee Benefits Expense Explanatory [Table Text Block] Disclosure Of Detailed Information About Employee Benefits Expense Explanatory Contract Liabilities [Roll Forward] Contract Liabilities [Roll Forward] Contract Liabilities Vesting percentage Annual Vesting Percentage Of Share Based Payment Arrangement Annual Vesting Percentage Of Share Based Payment Arrangement Total depreciation and impairment charge Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss Cash And Cash Equivalents [Table] Cash And Cash Equivalents [Table] Cash And Cash Equivalents [Table] Equity investments Equity investments [member] CGU External Business of InstaDeep External Business of InstaDeep [Member] External Business of InstaDeep Investing activities Cash flows from (used in) investing activities [abstract] Proposed dividends per share (in euros per share) Dividends proposed or declared before financial statements authorised for issue but not recognised as distribution to owners per share Risk-free interest rate Risk free interest rate, share options granted Reclassifications Reclassifications Of Property, Plant And Equipment Reclassifications Of Property, Plant And Equipment Shares issued (in shares) Number of instruments or interests issued or issuable Cash and Cash Equivalents Description of accounting policy for determining components of cash and cash equivalents [text block] Weighted Average Fair Value At Modification Date Of Share Options Modified Weighted Average Fair Value At Modification Date Of Share Options Modified Weighted Average Fair Value At Modification Date Of Share Options Modified Loss on derivative instruments at fair value through profit or loss Loss On Derivative Instruments At Fair Value [Member] Loss On Derivative Instruments At Fair Value Share-based payments Increase (decrease) through share-based payment transactions, equity Non-deductible expenses and other permanent differences Tax Effect Of Expense Not Deductible In Determining Taxable Profit (Tax Loss), Net Of Addiitonal Deductions Tax Effect Of Expense Not Deductible In Determining Taxable Profit (Tax Loss), Net Of Addiitonal Deductions Awards paid one year after reaching target Percentage Of American Depository Shares To Ordinary Shares Percentage Of American Depository Shares To Ordinary Shares Total non-current assets Total non-current assets Non-current assets Exchange differences on translation of foreign operations Other comprehensive income, net of tax, exchange differences on translation of foreign operations Other Funds Other Funds [Member] Other Funds Employee Stock Option Plan Employee Stock Option Plan [Member] Employee Stock Option Plan Contract assets As of January 1 As of December 31 Non-current contract assets Classes of property, plant and equipment [axis] Classes of property, plant and equipment [axis] Classes of property, plant and equipment [domain] Classes of property, plant and equipment [domain] New Technologies Re​ New Technologies Re​ [Member] New Technologies Re​ thereof un-vested (in shares) Number Of Share Options Unested In Share-Based Payment Arrangement Number Of Share Options Unested In Share-Based Payment Arrangement Entity Address, Country Entity Address, Country BioNTech Innovation and Services Marburg GmbH BioNTech Innovation and Services Marburg GmbH [Member] BioNTech Innovation and Services Marburg GmbH Disclosure of reconciliation of changes in intangible assets and goodwill [line items] Disclosure of reconciliation of changes in intangible assets and goodwill [line items] BioNTech USA Holding, LLC BioNTech USA Holding, LLC [Member] BioNTech USA Holding, LLC Change in cash and cash equivalents resulting from exchange rate differences Effect of exchange rate changes on cash and cash equivalents Contract assets As of January 1 As of December 31 Current contract assets Foreign Currencies Description of accounting policy for foreign currency translation [text block] Other Provisions Other Provisions [Member] Other Provisions Investment in DualityBio DualityBio [Member] DualityBio Document Annual Report Document Annual Report Contract liabilities As of January 1 As of December 31 Non-current contract liabilities Disclosure Of Income And Expenses [Table] Disclosure Of Income And Expenses [Table] Disclosure Of Income And Expenses Trade and other receivables Trade and other current receivables Change in fair value with increasing input factor (in millions €) Increase in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, liabilities Effective exercise price maximum (in dollars per share) Effective Exercise Price Maximum Effective Exercise Price Maximum Entity Interactive Data Current Entity Interactive Data Current Corporate tax rate (as a percent) Corporate Tax Rate Corporate Tax Rate Summary of Goodwill Recognized Disclosure Of Goodwill Acquired In Respective Business Combinations Explanatory [Table Text Block] Disclosure Of Goodwill Acquired In Respective Business Combinations Explanatory Assets [Roll Forward] Assets [Roll Forward] Assets Other Non-Financial Liabilities Disclosure of other liabilities [text block] Construction in progress and advance payments Construction In Progress And Advance Payments [Member] Construction In Progress And Advance Payments Bristol-Myers Squibb Bristol-Myers Squibb [Member] Bristol-Myers Squibb Fair value measurement derivative Accumulated increase (decrease) in fair value of credit derivatives or similar instruments related to financial assets designated as measured at fair value through profit or loss Levels of fair value hierarchy [axis] Levels of fair value hierarchy [axis] BioNTech Pharmaceuticals Spain S.L BioNTech Pharmaceuticals Spain S.L [Member] BioNTech Pharmaceuticals Spain S.L Impairment loss recognised in other comprehensive income, right-of-use assets Impairment loss recognised in other comprehensive income, right-of-use assets Finance expenses Total finance expenses Finance costs Summary of Financial Assets at Amortized Cost and at Fair Value through Profit or Loss Disclosure of financial assets [text block] Employee Stock Ownership Plan 2020 Employee Stock Ownership Plan 2020 [Member] Employee Stock Ownership Plan 2020 Additions from business combinations Acquisitions through business combinations, property, plant and equipment Exercise price in translation for IPO (in dollar per share and euro per share) Exercise Price Currency Translation Of Public Offering Price Per Share Exercise Price Currency Translation Of Public Offering Price Per Share Significant Accounting Policies Disclosure of material accounting policy information [text block] Financial Statement Line Items [Domain] Financial Statement Line Items [Domain] Financial Statement Line Items [Domain] Employee Stock Ownership Plan 2018 Employee Stock Ownership Plan 2018 [Member] Employee Stock Ownership Plan 2018 Inventory write-offs Inventory write-down Ownership [Domain] Ownership [Domain] thereof vested (in shares) Number Of Share Options Vested In Share-Based Payment Arrangement Number Of Share Options Vested In Share-Based Payment Arrangement Entity Central Index Key Entity Central Index Key Settled (in shares) Number Of Other Equity Instruments Settled In Share-Based Payment Arrangement Number Of Other Equity Instruments Settled In Share-Based Payment Arrangement Net other comprehensive income / (loss) that may be reclassified to profit or loss in subsequent periods Other comprehensive income that will be reclassified to profit or loss, net of tax Share options outstanding (in shares) Beginning balance (in shares) Ending balance, (in shares) (Phantom) share options outstanding (expected to be allocated) (in shares) Number of share options outstanding in share-based payment arrangement Consideration Acquisition-date fair value of total consideration transferred [abstract] InstaDeep France SAS InstaDeep France SAS [Member] InstaDeep France SAS Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination Acquisition-related costs for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination Earnings / (Loss) per share Basic earnings per share [abstract] Attributable to: Profit (loss), attributable to [abstract] Net amount spend Share Repurchase Program, Net Amount Spent Share Repurchase Program, Net Amount Spent Profit (loss) of acquiree if combination occurred at beginning of period Profit (loss) of combined entity as if combination occurred at beginning of period Equity and liabilities Equity and liabilities [abstract] Entity Filer Category Entity Filer Category 1 to 5 years Later than two years and not later than five years [member] thereof: attributable to performance obligations satisfied in prior periods Current Contract Assets Attibutable To Performance Obligations Satisfied In Prior Periods Current Contract Assets Attibutable To Performance Obligations Satisfied In Prior Periods Average rate Average foreign exchange rate Change in valuation allowance Tax Effect Of Change In Valuation Allowance Tax Effect Of Change In Valuation Allowance Intrinsic value of exercised options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value1 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value1 Additions Additions other than through business combinations, property, plant and equipment Operating profit / (loss) Profit (loss) from operating activities Vested Vested [Member] Vested Increase (Decrease) In Contract Assets Increase (Decrease) In Contract Assets Increase (Decrease) In Contract Assets Intangible assets with indefinite useful life Intangible assets with indefinite useful life Entity Address, Address Line One Entity Address, Address Line One Threshold amount of dividend by number of shares outstanding immediately following initial public offering Threshold Amount Of Dividend By Number Of Shares Outstanding Immediately Following Initial Public Offering Threshold Amount Of Dividend By Number Of Shares Outstanding Immediately Following Initial Public Offering Commercial Paper Commercial Paper 1 [Member] Commercial Paper 1 JPT Peptide Technologies Inc. JPT Peptide Technologies Inc. [Member] JPT Peptide Technologies Inc. Leases Disclosure of leases [text block] Investment in other financial assets Other cash payments to acquire interests in joint ventures, classified as investing activities Ownership [Axis] Ownership [Axis] Beginning balance (in shares) Ending balance (in shares) Number Of Ordinary Shares Underlying Options Outstanding Number Of Ordinary Shares Underlying Options Outstanding Disclosure of Contract Assets Disclosure Of Contract Assets [Table Text Block] Disclosure Of Contract Assets Employee Stock Ownership Plan Equity Settled Employee Stock Ownership Plan Equity Settled [Member] Employee Stock Ownership Plan Equity Settled Summary of Expense Recognized for Employee Services Received Explanation of effect of share-based payments on entity's profit or loss [text block] Commitments under purchase agreements for property, plant and equipment Contractual commitments for acquisition of property, plant and equipment Consolidated structured entities [domain] Consolidated structured entities [domain] Upfront payment, acquisition of intangible asset Upfront Payment, Acquisition of Intangible Asset Upfront Payment, Acquisition of Intangible Asset Contingent revenues from remaining performance obligations Contingent Revenues From Remaining Performance Obligations Contingent Revenues From Remaining Performance Obligations Provisions Disclosure of provisions [text block] Statement of cash flows [abstract] Weighted average exercise price (€) Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price Disclosure of financial assets [table] Disclosure of financial assets [table] Title and Position [Domain] Title and Position [Domain] Entity Listings [Line Items] Entity Listings [Line Items] State tax credits Accumulated Tax Losses In State Tax Credits Accumulated Tax Losses In State Tax Credits Adjustment prior year taxes Adjustments for current tax of prior periods Increase (decrease) in finance income (costs) Increase (Decrease) In Finance Income (Costs) Increase (Decrease) In Finance Income (Costs) Percentage of target share price applicable for prior twelve month period (as a percent) Percentage Of Target Share Price Applicable For Prior Twelve Month Percentage Of Target Share Price Applicable For Prior Twelve Month Cabt-Bio (Hong Kong) Ltd. Cabt-Bio (Hong Kong) Ltd. [Member] Cabt-Bio (Hong Kong) Ltd. Settlement of pre-existing relationships Settlement of pre-existing relationships Settlement of pre-existing relationships Counterparty Name [Domain] Counterparty Name [Domain] BioNTech (Shanghai) Pharmaceuticals Co. Ltd. BioNTech (Shanghai) Pharmaceuticals Co. Ltd. [Member] BioNTech (Shanghai) Pharmaceuticals Co. Ltd. Pension costs Post-employment benefit expense in profit or loss, defined benefit plans Germany GERMANY Deviation due to deviating income tax rate (Germany and foreign countries) Tax effect of foreign tax rates Loans and borrowings Loans And Borrowings [Member] Loans And Borrowings Other employee expense Other employee expense Prepayments related to service contracts Current Prepayments Related To Service Contracts Current Prepayments Related To Service Contracts Current liabilities Current liabilities [abstract] Current Current Contract Assets [Roll Forward] Current Contract Assets Work in progress and advance payments Advance Payments [Member] Advance Payments thereof vested (in shares) Number Of Ordinary Shares Underlying Options Vested In Share-based Payment Arrangement Number Of Ordinary Shares Underlying Options Vested In Share-based Payment Arrangement Additions Purchases, fair value measurement, liabilities Other financial liabilities Other current financial liabilities Disclosure of transactions between related parties [line items] Disclosure of transactions between related parties [line items] Disclosure Of Corporate Information Explanatory [Abstract] Disclosure Of Corporate Information Explanatory [Abstract] Disclosure Of Corporate Information Explanatory [Abstract] Other comprehensive income Other comprehensive income [abstract] Contractual obligation to acquire intangible assets Contractual commitments for acquisition of intangible assets Summary of Reconciliation of Expected Income Tax Benefit to Actual Income Tax Benefit Disclosure Of Reconciliation Of Expected Income Tax Benefit To Actual Income Tax Benefit Explanatory [Table Text Block] Disclosure Of Reconciliation Of Expected Income Tax Benefit To Actual Income Tax Benefit Explanatory Other Operating Equipment [Member] Other Operating Equipment [Member] Other Operating Equipment Investment in Autolus Autolus [Member] Autolus Classes of share capital Classes of share capital [domain] CHINA CHINA Contact Personnel Email Address Contact Personnel Email Address Gains from financial assets or financial liabilities that are mandatorily measured at fair value through profit or loss Gains (losses) on financial assets at fair value through profit or loss, mandatorily measured at fair value Finance income Finance income Finance income Classes of financial liabilities [axis] Classes of financial liabilities [axis] Austria AUSTRIA Summary of Cash and Cash Equivalents Disclosure Of Cash And Cash Equivalents Explanatory [Table Text Block] Disclosure Of Cash And Cash Equivalents Explanatory Classes of financial liabilities Classes of financial liabilities [domain] Document Shell Company Report Document Shell Company Report Settlement Of Non-Contractual Pre-Existing Relationships Settlement Of Non-Contractual Pre-Existing Relationships Settlement Of Non-Contractual Pre-Existing Relationships Disclosure of other provisions [line items] Disclosure of other provisions [line items] Additions to right-of-use assets Additions to right-of-use assets Royalty Assets Royalty Assets [Member] Royalty Assets Other Operating Income (Expense) Other Operating (Expense) Income [Member] Other Operating (Expense) Income Acquisition of subsidiaries and businesses, net of cash acquired Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities Summary of Revenue Recognized Disclosure Of Recognition Of Revenue Explanatory [Table Text Block] Disclosure Of Recognition Of Revenue Explanatory Share Repurchase Program, Tranche One Share Repurchase Program, Tranche One [Member] Share Repurchase Program, Tranche One Reclassifi-cation Increase Decrease Through Reclassification, Liabilities Arising From Financing Activities Increase Decrease Through Reclassification, Liabilities Arising From Financing Activities Contract liabilities Contract Liabilities [Member] Contract Liabilities Other Non-Financial Liabilities [Abstract] Other Non-Financial Liabilities Share repurchase program Share Repurchase Program Classified As Financing Activities Share Repurchase Program Classified As Financing Activities Lease liabilities Lease liabilities Lease liabilities Investments in equity instruments designated at fair value through other comprehensive income [domain] Investments in equity instruments designated at fair value through other comprehensive income [domain] COVID-19 vaccine revenues COVID-19 Vaccine Revenues [Member] COVID-19 Vaccine Revenues Other Increase (decrease) through other changes, liabilities arising from financing activities Summary of Information about Entity with Significant Influence Over Group Disclosure Of Entity With Significant Influence Over Group Explanatory [Table Text Block] Disclosure Of Entity With Significant Influence Over Group Explanatory Provisions Total non-current Non-current provisions InstaDeep Tunisia SARL InstaDeep Tunisia SARL [Member] InstaDeep Tunisia SARL Current obligations under lease contracts Current Obligations Under Lease Contracts [Member] Current Obligations Under Lease Contracts Timing of transfer of goods or services [axis] Timing of transfer of goods or services [axis] Minimum Minimum [Member] Liabilities arising from financing activities Liabilities arising from financing activities [domain] Summary of Number and Share Price of Restricted Stock Units Disclosure of number and weighted average exercise prices of other equity instruments [text block] Additions Purchases, fair value measurement, assets Disposals Disposals, intangible assets and goodwill Bargain purchase Bargain Purchase [Member] Bargain Purchase Share capital Issued capital Disclosure of reconciliation of liabilities arising from financing activities [line items] Disclosure of reconciliation of liabilities arising from financing activities [line items] Other Intangible Assets and Goodwill Disclosure of intangible assets and goodwill [text block] Gains (losses) recognised in profit or loss including exchange differences, fair value measurement, assets Gains (losses) recognised in profit or loss including exchange differences, fair value measurement, assets Categories of financial assets [axis] Categories of financial assets [axis] Timing of transfer of goods or services Timing of transfer of goods or services [domain] Exercise price (in euros per share) Exercise price, share options granted Number of shares outstanding (in shares) Number of shares outstanding BioNTech Innovation GmbH BioNTech Innovation GmbH [Member] BioNTech Innovation GmbH Fixed assets Fixed Assets [Member] Fixed Assets BioNTech Delivery Technologies GmbH BioNTech Delivery Technologies GmbH [Member] BioNTech Delivery Technologies GmbH Other Other provisions Financial liabilities Beginning balance Ending balance Financial liabilities Disclosure of reserves within equity [line items] Disclosure of reserves within equity [line items] Income taxes Income taxes Income taxes Tax expense (income) Significant unobservable input, liabilities Significant unobservable input, liabilities Events After the Reporting Period Disclosure of events after reporting period [text block] Document Transition Report Document Transition Report CureVac Belgium SA CureVac Belgium SA [Member] CureVac Belgium SA Operating activities Cash flows from (used in) operating activities [abstract] Contingent consideration Contingent liabilities recognised in business combination Additions from business combinations Increase (Decrease) In Current Contract Liabilities From Business Combinations Increase (Decrease) In Current Contract Liabilities From Business Combinations Document Period End Date Document Period End Date BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. [Member] BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. +5% Positive Five Percentage Change In Foreign Exchange Rate [Member] Positive Five Percentage Change In Foreign Exchange Rate AT Impf GmbH AT Impf GmbH [Member] AT Impf GmbH Non-adjusting events after reporting period Non-adjusting events after reporting period [domain] Increase (decrease) through net exchange differences, right-of-use assets Increase (decrease) through net exchange differences, right-of-use assets Maturity [axis] Maturity [axis] CGU External Product Sales of JPT External Product Sales To JPT [Member] External Product Sales To JPT United Kingdom UNITED KINGDOM Recognized directly in equity Deferred tax relating to items credited (charged) directly to equity Classes of financial instruments [axis] Classes of financial instruments [axis] Goodwill Goodwill Associates [axis] Associates [axis] Key management personnel compensation, signing bonus Key Management Personnel Compensation, Signing Bonus Key Management Personnel Compensation, Signing Bonus Other gains from financial assets subsequently measured at amortized cost Gains (losses) on financial assets at amortised cost Fixed compensation Key Management Personnel Compensation, Fixed Compensation Key Management Personnel Compensation, Fixed Compensation Fair Value Per Share Fair Value Per Share Fair Value Per Share Document Type Document Type Total Expense recognized for employee services received Expense from share-based payment transactions with employees Performance Restricted Stock Units Performance Restricted Stock Units [Member] Performance Restricted Stock Units Product and Service [Axis] Product and Service [Axis] Restricted Stock Units Restricted Stock Units [Member] Restricted Stock Units Classes of financial assets [axis] Classes of financial assets [axis] Impairment losses and reversals of impairment losses on financial assets (operating result), net Impairment losses and reversals of impairment losses on financial assets (operating result), net [Member] Impairment losses and reversals of impairment losses on financial assets (operating result), net BioNTech Australia Pty Ltd. BioNTech Australia Pty Ltd. [Member] BioNTech Australia Pty Ltd. Profit or loss [abstract] Contract liabilities As of January 1 As of December 31 Current contract liabilities Statistical Measurement [Axis] Statistical Measurement [Axis] Increase (Decrease) In Equity From Modifications Of Share-Based Payment Arrangements Increase (Decrease) In Equity From Modifications Of Share-Based Payment Arrangements Increase (Decrease) In Equity From Modifications Of Share-Based Payment Arrangements Vesting period Share Based Vesting Period Share Based Vesting Period Revenue of acquiree if combination occurred at beginning of period Revenue of combined entity as if combination occurred at beginning of period Classes of assets [axis] Classes of assets [axis] Provisions Total current Current provisions Foreign exchange differences, net Foreign Exchange Differences [Member] Foreign Exchange Differences Estimated milestone payment to be received Estimated Milestone Payment To Be Received At Contract Inception Estimated Milestone Payment To Be Received At Contract Inception Summary of Significant Unobservable Inputs (Level 3) Used for Recurring Fair Value Measurements and the Effect of the Measurements Disclosure of significant unobservable inputs used in fair value measurement of assets [text block] Share-based payments Types of share-based payment arrangements [domain] Rest of the World Rest of the World [Member] Rest of the World Earnings / (Loss) per share Earnings per share [abstract] Cash-Settled Share-Based Payment Arrangement Cash-Settled Share-Based Payment Arrangement [Member] Cash-Settled Share-Based Payment Arrangement Range [axis] Range [axis] Revenue from collaboration agreements Revenue From Collaboration Agreements Revenue From Collaboration Agreements Components of equity [axis] Components of equity [axis] Summary of Financial Liabilities at Amortized Cost and at Fair Value through Profit or Loss Summary of Financial Liabilities at Amortized Cost Disclosure of financial liabilities [text block] Other Other Current Assets, Other Other Current Assets, Other Share repurchase program authorized amount Share Repurchase Program Authorized Amount Share Repurchase Program Authorized Amount Change in cash and cash equivalents resulting from other valuation effects Effect Of Other Valuation Changes On Cash And Cash Equivalents Effect Of Other Valuation Changes On Cash And Cash Equivalents Disclosure of financial liabilities [line items] Disclosure of financial liabilities [line items] Profit / (Loss) before tax Profit / (Loss) before tax Profit / (Loss) before tax Profit (loss) before tax Capital reserve Capital reserve Currency effects functional currency Currency Effects Of Contract Liabilities Currency Effects Of Contract Liabilities Reclassification for share-based payment arrangement Reclassification Of Share-Based Payment Arrangement Reclassification Of Share-Based Payment Arrangement BioNTech Real Estate Holding GmbH BioNTech Real Estate Holding GmbH [Member] BioNTech Real Estate Holding GmbH Issued Capital and Reserves Disclosure of share capital, reserves and other equity interest [text block] Expected revenues from remaining performance obligations Expected Revenues From Remaining Performance Obligations Expected Revenues From Remaining Performance Obligations Categories of related parties Categories of related parties [domain] Management Board Grant PSUs Management Board Grant PSUs [Member] Management Board Grant PSUs LTI 2024 program - RSUs Employee Equity Plan, Long-Term Incentive 2024 Program, RSUs [Member] Employee Equity Plan, Long-Term Incentive 2024 Program, RSUs Current Current Contract Liabilities [Roll Forward] Current Contract Liabilities Other Other Income Expense [Member] Other Income Expense Classes of financial instruments Classes of financial instruments [domain] Disclosure of detailed information about business combination [table] Disclosure of detailed information about business combination [table] Auditor Location Auditor Location Recognized through business combinations Increase (decrease) through business combinations, deferred tax liability (asset) Intangible Assets [Abstract] Intangible Assets [Abstract] Intangible Assets [Abstract] Interest received and realized gains from cash and cash equivalents Interest received, classified as operating activities Recognition as revenues Increase (Decrease) In Non-Current Contract Liabilities Increase (Decrease) In Non-Current Contract Liabilities Business Combinations [Abstract] Business Combinations 1 [Abstract] Business Combinations 1 Foreign exchange differences, net Net foreign exchange loss InstaDeep RSU Program Employees InstaDeep RSU Program Employees [Member] InstaDeep RSU Program Employees Weighted average number of ordinary shares outstanding for basic EPS (in shares) Weighted average number of ordinary shares used in calculating basic earnings per share Other additions Other additions Increase (Decrease) In Contract Liabilities Increase (Decrease) In Contract Liabilities CGU Immunotherapies CGU Immunotherapies [Member] CGU Immunotherapies Increase of research and development expense Increase (Decrease) Of Research And Development Expense Increase (Decrease) Of Research And Development Expense German Federal Ministry of Health German Federal Ministry of Health [Member] German Federal Ministry of Health Summary of Deferred Taxes Disclosure of temporary difference, unused tax losses and unused tax credits [text block] Disclosure of detailed information about intangible assets [table] Disclosure of detailed information about intangible assets [table] Other reserves Other reserves Share-based payments (incl. long-term incentive) Key management personnel compensation, share-based payment Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Other Investments Other Investments 1 [Member] Other Investments 1 BioNTech UK Ltd. BioNTech UK Ltd. [Member] BioNTech UK Ltd. Transaction costs Acquisition-related costs recognised as expense for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination Impairment Impairment loss recognised in profit or loss, property, plant and equipment Major customers Major customers [domain] Currency effects functional currency Currency Effects Of Non-Current Contract Liabilities Currency Effects Of Non-Current Contract Liabilities Summary of Amounts Recognized in Consolidated Statement of Operations Disclosure Of Detailed Information About Lease Expense Recognized In Statement Of Operations Explanatory [Table Text Block] Disclosure Of Detailed Information About Lease Expense Recognized In Statement Of Operations Explanatory Net cash flows used in financing activities Cash flows from (used in) financing activities Reclassifications Increase (decrease) through transfers and other changes, intangible assets and goodwill Equity-settled share-based payment transactions, fair value at grant date Equity-Settled Share-Based Payment Transactions, Fair Value At Grant Date Equity-Settled Share-Based Payment Transactions, Fair Value At Grant Date MediLink Therapeutics Co., Ltd MediLink Therapeutics Co., Ltd [Member] MediLink Therapeutics Co., Ltd Cumulative depreciation and impairment charges Accumulated depreciation, amortisation and impairment [member] Entity Current Reporting Status Entity Current Reporting Status Tax rate for deferred taxes (as a percent) Tax Rate On Deferred Taxes Tax Rate On Deferred Taxes Treasury shares Treasury shares Cash Outflow From Share-Based Payment Arrangements Cash Outflow From Share-Based Payment Arrangements Cash Outflow From Share-Based Payment Arrangements Standards Issued but Not Yet Effective Description Of Accounting Policy For Standards Issued But Not Yet Effective Explanatory [Policy Text Block] Description Of Accounting Policy For Standards Issued But Not Yet Effective Explanatory Statement of changes in equity [table] Statement of changes in equity [table] Pipeline Prioritization Costs Pipeline Prioritization Costs [Member] Pipeline Prioritization Costs Reclassification from non-current to current Reclassification From Non-Current To Current, Non-Current Contract Liabilities Reclassification From Non-Current To Current, Non-Current Contract Liabilities Corporate tax Accumulated Tax Losses In Corporate Tax Accumulated Tax Losses In Corporate Tax Liabilities From Share-Based Payment Transactions, Non-Current Liabilities From Share-Based Payment Transactions, Non-Current Liabilities From Share-Based Payment Transactions, Non-Current Cost of sales Cost of sales Cost of sales Classes of assets [domain] Classes of assets [domain] Current Fiscal Year End Date Current Fiscal Year End Date Announcement Of Research, Development And Commercialization Collaboration Agreement Announcement Of Research, Development And Commercialization Collaboration Agreement [Member] Announcement Of Research, Development And Commercialization Collaboration Agreement DeepChain Technology DeepChain Technology [Member] DeepChain Technology Ireland IRELAND Minimum Bottom of range [member] CureVac SE CureVac SE [Member] CureVac SE Additions Increase (Decrease) In Non-Current Contract Assets Increase (Decrease) In Non-Current Contract Assets Categories of related parties [axis] Categories of related parties [axis] Impairment of Non-Financial Assets Description of accounting policy for impairment of non-financial assets [text block] Effects Reconciliation of accounting profit multiplied by applicable tax rates [abstract] Other variable compensation Key Management Personnel Compensation, Other Variable Compensation Key Management Personnel Compensation, Other Variable Compensation (Decrease) / Increase in trade payables, other financial liabilities, other liabilities, contract liabilities, refund liabilities and provisions Adjustments For Increase (Decrease) In Trade Payables, Other Liabilities, Contract Liabilities And Provisions Adjustments For Increase (Decrease) In Trade Payables, Other Liabilities, Contract Liabilities And Provisions Net profit / (loss) Net profit / (loss) Profit (loss) Reclassification Io Trade Accounts Receivables, Contract Assets Reclassification Io Trade Accounts Receivables, Contract Assets Reclassification Io Trade Accounts Receivables, Contract Assets Total Beginning balance Ending balance Financial assets Treasury shares (in shares) Number Of Shares Held In Treasury Number Of Shares Held In Treasury Purchases of property and other assets from entities controlled by ATHOS KG Purchases of property and other assets, related party transactions Granted, weighted-average exercise price (in euros per share) Weighted average exercise price of share options granted in share-based payment arrangement Minimum strike price (as a percent) Exercise Of Option Rights, Minimum Strike Price Percent Exercise Of Option Rights, Minimum Strike Price Percent Total non-current liabilities Non-current liabilities Closing rate Closing foreign exchange rate Property, plant and equipment and right-of-use assets Property, plant and equipment recognised as of acquisition date Proceeds from sale of property, plant and equipment Proceeds (Payments) From Sales Or Destructions Of Property, Plant And Equipment, Classified As Investing Activities Proceeds (Payments) From Sales Or Destructions Of Property, Plant And Equipment, Classified As Investing Activities Cash at banks and on hand Cash At Banks And On Hand [Member] Cash At Banks And On Hand Document Registration Statement Document Registration Statement Shares issued (in shares) Number of shares issued Total depreciation and impairment charge Depreciation, right-of-use assets Temporary difference, unused tax losses and unused tax credits Temporary difference, unused tax losses and unused tax credits [domain] Listed equity investments Listed Equity Investments [Member] Listed Equity Investments InstaDeep Employee Stock Ownership Awards InstaDeep Employee Stock Ownership Awards [Member] InstaDeep Employee Stock Ownership Awards Retained earnings Retained earnings [member] Increase of general and administrative expense Increase (Decrease) Of General And Administrative Expense Increase (Decrease) Of General And Administrative Expense Repos Repos [Member] Repos Employee Stock Ownership Plan (ESOP) Name [Axis] Employee Stock Ownership Plan (ESOP) Name [Axis] Employee Stock Ownership Plan (ESOP) Name Disclosure of contingent liabilities [table] Disclosure of contingent liabilities [table] Leases Description of accounting policy for leases [text block] Bargain from the acquisition Bargain From The Acquisition, Acquisition-Date Fair Value Bargain From The Acquisition, Acquisition-Date Fair Value Analysis of income and expense [abstract] Business Contact Business Contact [Member] Valuation adjustment Valuation Adjustment [Member] Valuation Adjustment Liabilities Liabilities [abstract] Total consideration Assets Acquired (Liabilities Assumed), Including Goodwill Assets Acquired (Liabilities Assumed), Including Goodwill Price of ADS as a percentage of exercise price, maximum (as a percent) Price Of American Depository Share As A Percentage Of Exercise Price, Maximum Price Of American Depository Share As A Percentage Of Exercise Price, Maximum Categories of financial assets Categories of financial assets [domain] LTI 2023 program Employee Equity Plan, Long-Term Incentive 2023 Program [Member] Employee Equity Plan, Long-Term Incentive 2023 Program Carrying amount Carrying amount [member] Settled (in shares) Number Of Share Options Settled In Share-based Payment Arrangement Number Of Share Options Settled In Share-based Payment Arrangement Working capital adjustments: Working Capital Adjustments [Abstract] Working Capital Adjustments Unobservable inputs [domain] Unobservable inputs [domain] Increase of sales and marketing expense Increase (Decrease) Of Sales And Marketing Expense Increase (Decrease) Of Sales And Marketing Expense Short-term incentive – first installment(2) Key management personnel compensation, short-term employee benefits Security Exchange Name Security Exchange Name In-process R&D In Process R&D [Member] In Process R&D All Other Members All Other Members [Member] All Other Members Investments in equity instruments designated at fair value through other comprehensive income Total Investments in equity instruments designated at fair value through other comprehensive income Other revenues Other Sales [Member] Other Sales Forfeited (in shares) Number of share options forfeited in share-based payment arrangement Disclosure of Provisions Disclosure Of Provisions [Table Text Block] Disclosure Of Provisions Summary of Inputs Used in Measurement of Fair Value at Grant Date Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block] Right-of-use assets Right-of-use assets Estimated Allocation Date Seven Employee Stock Options Estimated Allocation Date Seven Employee Stock Options [Member] Estimated Allocation Date Seven Employee Stock Options Total Intangible Assets With Indefinite Useful Life And Goodwill Intangible Assets With Indefinite Useful Life And Goodwill Capital reserve Capital reserve [member] Contact Personnel Name Contact Personnel Name Percentage of voting equity interests acquired (as a percent) Percentage of voting equity interests acquired Obligations from onerous contracts Current onerous contracts provision Applicable wage taxes and social security contributions resulting from and withheld upon exercise Payables on social security and taxes other than income tax Option rights exercisable period (in years) Option Exercisable Period Option Exercisable Period Government and similar grants Government grants Intangible assets other than goodwill [member] Intangible assets other than goodwill [member] Outstanding balances of related party transactions Provisions for doubtful debts related to outstanding balances of related party transaction Entity Listings [Table] Entity Listings [Table] BioNTech Manufacturing GmbH BioNTech Manufacturing GmbH [Member] BioNTech Manufacturing GmbH Other comprehensive income that may be reclassified to profit or loss in subsequent periods, net of tax Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract] As of January 1 Contract liabilities at beginning of period As of December 31 Contract liabilities Statistical Measurement [Domain] Statistical Measurement [Domain] Revenues from out-licensing Revenues from out-licensing [Member] Revenues from out-licensing BioNTech Cell & Gene Therapies GmbH BioNTech Cell & Gene Therapies GmbH [Member] BioNTech Cell & Gene Therapies GmbH Cash at banks and on hand Reimbursement Asset [Member] Reimbursement Asset Tax losses Unused tax losses [member] Joint Arrangements Description of accounting policy for investments in joint ventures [text block] Liability related to the phantom option awards Phantom Option Awards, Liability Phantom Option Awards, Liability Liabilities arising from financing activities [axis] Liabilities arising from financing activities [axis] Cash And Cash Equivalents [Line Items] Cash And Cash Equivalents 1 [Line Items] Cash And Cash Equivalents 1 Other financial assets Other non-current financial assets Share-based payments Share based Payments, Classified As Operating Activities Share based Payments, Classified As Operating Activities Useful life measured as period of time, intangible assets other than goodwill (in years) Useful life measured as period of time, intangible assets other than goodwill Classes of share capital [axis] Classes of share capital [axis] Cash-settled option rights, exercised (in shares) Exercised, share options (in shares) Exercised (in shares) Number of share options exercised in share-based payment arrangement Basis of Consolidation Disclosure of basis of consolidation [text block] Summary of Finance Income and Costs Disclosure Of Finance Income and Costs Explanatory [Table Text Block] Disclosure Of Finance Income and Costs Explanatory Total equity Equity at beginning of period Equity at end of period Equity Research and development expenses Research And Development Expenses [Member] Research And Development Expenses Entity Addresses, Address Type [Axis] Entity Addresses, Address Type [Axis] Ordinary shares, no par value, with a notional amount attributable to each ordinary share of €1 Ordinary Shares, No Par Value, With National Amount Attributable To Each Ordinary Share [Member] Ordinary Shares, No Par Value, With National Amount Attributable To Each Ordinary Share Property, plant and equipment Property, plant and equipment, beginning balance Property, plant and equipment, ending balance Property, plant and equipment Provision related to usage Current Onerous Contracts Provision, Related To Usage Current Onerous Contracts Provision, Related To Usage Schedule of Other Financial Commitments Disclosure of commitments [text block] Reclassification from non-current to current Reclassification From Non-Current To Current, Contract Liabilities Reclassification From Non-Current To Current, Contract Liabilities Target incentive amount Share Based Compensation, Target Incentive Amount Share Based Compensation, Target Incentive Amount Ryvu Therapeutics S.A. Ryvu Therapeutics S.A. [Member] Ryvu Therapeutics S.A. Finance income (costs), percentage change Finance Income (Costs), Percentage Change Finance Income (Costs), Percentage Change Contingencies And Other Financial Commitments [Abstract] Contingencies And Other Financial Commitments [Abstract] Contingencies And Other Financial Commitments [Abstract] Management Board Management Board [Member] Management Board Trade tax Accumulated Tax Losses In Trade Tax Accumulated Tax Losses In Trade Tax Option term Option Term Option Term InstaDeep Employee Incentive Plan InstaDeep Employee Incentive Plan [Member] InstaDeep Employee Incentive Plan Research and Development Expenses Description of accounting policy for research and development expense [text block] Other non-financial liabilities Total current Other current non-financial liabilities Total Other non-financial assets Other non-financial assets Other comprehensive loss that will not be reclassified to profit or loss in subsequent periods, net of tax Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract] Level 1 Level 1 of fair value hierarchy [member] Biotheus (Hengqin) Co. Ltd. Biotheus (Hengqin) Co. Ltd. [Member] Biotheus (Hengqin) Co. Ltd. Medine GmbH Medine GmbH [Member] Medine GmbH Granted (in shares) Granted (in shares) Number of share options granted in share-based payment arrangement Contingent consideration Contingent consideration [member] Total Other non-financial liabilities Disclosure of detailed information about property, plant and equipment [line items] Disclosure of detailed information about property, plant and equipment [line items] Gain on derivative instruments at fair value through profit or loss Gain On Derivative Instruments At Fair Value Through Profit Or Loss [Member] Gain On Derivative Instruments At Fair Value Through Profit Or Loss Share Repurchase Program Period [Domain] Share Repurchase Program Period [Domain] Share Repurchase Program Period [Domain] Weighted average cost of capital (as a percent) Capitalisation rate of borrowing costs eligible for capitalisation Discount rate Discount rate, measurement input [member] Level 2 Level 2 of fair value hierarchy [member] Dividends paid, classified as financing activities Dividends paid, classified as financing activities Expense related to short-term leases and leases of low-value assets Expense Relating To Short Term Leases And Leases Of Low Value Assets For Which Recognition Exemption Has Been Used Expense Relating To Short Term Leases And Leases Of Low Value Assets For Which Recognition Exemption Has Been Used Beginning balance (in euros per share) Ending balance (in euros per share) Weighted average exercise price of share options outstanding in share-based payment arrangement Profit attributable to ordinary equity holders of the parent for basic earnings Profit (loss), attributable to owners of parent Short-term incentive – second installment Key Management Personnel Compensation, Short-Term Employee Benefits, Second Installment Key Management Personnel Compensation, Short-Term Employee Benefits, Second Installment Current loans and borrowings Current Loans and Borrowings [Member] Current Loans and Borrowings Percent increase (decrease) in other operating income (expense) Percent Increase (Decrease) In Other Operating Income (Expense) Percent Increase (Decrease) In Other Operating Income (Expense) Biotheus (Nantong) Co. Ltd. Biotheus (Nantong) Co. Ltd. [Member] Biotheus (Nantong) Co. Ltd. Sales and marketing expenses Sales and marketing expenses Sales and marketing expense Estimated Allocation Date Two Estimated Allocation Date Two [Member] Estimated Allocation Date Two Major customers [axis] Major customers [axis] Interest income from effective interest method Interest revenue calculated using effective interest method Deferred tax (assets) and liabilities, net recognized Beginning balance deferred tax assets net Ending balance deferred tax assets net Deferred tax liability (asset) Other non-cash (income) / loss Other adjustments for non-cash items Total current liabilities Current liabilities Disclosure Of Financial Assets And Liabilities [Line Items] Disclosure Of Financial Assets And Liabilities [Line Items] Disclosure Of Financial Assets And Liabilities [Line Items] Professor Ugur Sahin MD Professor Ugur Sahin MD [Member] Professor Ugur Sahin MD Other assets non-current and current Other Assets Non-current And Current Recognised As Of Acquisition Date Other Assets Non-current And Current Recognised As Of Acquisition Date Inventories Total Current inventories Deferred tax assets Deferred tax assets Deposits, Commercial Paper, Repos Deposits, Commercial Paper, Repos [Member] Deposits, Commercial Paper, Repos Document Accounting Standard Document Accounting Standard Additions from business combinations Increase (decrease) through obtaining or losing control of subsidiaries or other businesses, liabilities arising from financing activities Government and similar grants Government Grants [Member] Government Grants Disclosure of temporary difference, unused tax losses and unused tax credits [line items] Disclosure of temporary difference, unused tax losses and unused tax credits [line items] Options outstanding, weighted-average expected life (in years) Weighted average remaining contractual life of outstanding share options Deviation due to local tax basis Tax Effect Of Deviation Due To Local Tax Basis Tax Effect Of Deviation Due To Local Tax Basis Percentage of entity's revenue Percentage of entity's revenue Disclosure of quantitative information about right-of-use assets [line items] Disclosure of quantitative information about right-of-use assets [line items] Summary of Inventories Disclosure Of Classes Of Inventories Explanatory [Table Text Block] Disclosure Of Classes Of Inventories Explanatory Percentage of exercise price increase (as a percent) Percentage Of Increase In Exercise Price Percentage Of Increase In Exercise Price Other financial assets Other Financial Assets [Member] Other Financial Assets Share-Based Payments Description of accounting policy for share-based payment transactions [text block] Statement of changes in equity [abstract] BioNTech Discovery GmbH BioNTech Discovery GmbH [Member] BioNTech Discovery GmbH Retained earnings Retained earnings Summary of Fair Values of Identifiable Net Assets Disclosure of detailed information about business combination [text block] Investments in equity instruments designated at fair value through other comprehensive income [axis] Investments in equity instruments designated at fair value through other comprehensive income [axis] Other (incl. deferred expenses) Other Deferred Taxes [Member] Other Deferred Taxes InstaDeep DE GmbH InstaDeep DE GmbH [Member] InstaDeep DE GmbH General and administrative expenses General And Administrative Expenses [Member] General And Administrative Expenses Summary of Information about Parent Company Disclosure Of Significant Investments By Parent Company Explanatory [Table Text Block] Disclosure Of Significant Investments By Parent Company Explanatory Rights and Other Clinical Pipeline Candidates Rights and Other Clinical Pipeline Candidates [Member] Rights and Other Clinical Pipeline Candidates Key management personnel compensation, severance Key management personnel compensation, Severance Key management personnel compensation, Severance Significant unobservable input, assets Significant unobservable input, assets Buildings [member] Buildings [member] Granted (in shares) Number of other equity instruments granted in share-based payment arrangement Types of risks Types of risks [domain] Undiscounted potential future lease payments related to renewal options not included in lease liabilities until 2049 Undiscounted Future Lease Payments Related To Renewal Options Not Included In Lease Liabilities Undiscounted Future Lease Payments Related To Renewal Options Not Included In Lease Liabilities Contact Personnel Fax Number Contact Personnel Fax Number Subsidiaries [axis] Subsidiaries [axis] Disclosure of Other Operating Result Disclosure Of Other Operating Result [Table Text Block] Disclosure Of Other Operating Result Income and Expenses Disclosure Of Income And Expense Explanatory [Text Block] Disclosure Of Income And Expense Explanatory Interest paid and realized losses from cash and cash equivalents Interest paid, classified as operating activities Change in deferred taxes due to tax rate change Tax effect from change in tax rate Geographical [Domain] Geographical [Domain] Disclosure of financial liabilities [table] Disclosure of financial liabilities [table] Segment Information Description of accounting policy for segment reporting [text block] Summary of Other Assets Disclosure Of Detailed Information About Other Assets Explanatory [Table Text Block] Disclosure Of Detailed Information About Other Assets Explanatory Total Contract Assets [Roll Forward] Contract Assets Finance income excluding foreign exchange differences Adjustments for finance income Beginning balance Ending balance Liabilities arising from financing activities Reclassification from non-current to current Reclassification From Non-Current To Current, Contract Assets Reclassification From Non-Current To Current, Contract Assets LTI 2021 program Employee Equity Plan, Long-Term Incentive 2021 Program [Member] Employee Equity Plan, Long-Term Incentive 2021 Program Non-current Non-current lease liabilities Proceeds from maturity of other financial assets (Investment) Proceeds From Maturity Of Other Financial Assets, Classified As Investing Activities (Investment) Proceeds From Maturity Of Other Financial Assets, Classified As Investing Activities Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [Domain] Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [Domain] Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount Revenues from Contracts with Customers Disclosure of revenue from contracts with customers [text block] BioNTech 2020 and 2024 Restricted Stock Unit Plans for Non-North American Employees BioNTech Employee Equity Plan For Employees Based In Europe [Member] BioNTech Employee Equity Plan For Employees Based In Europe Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Bad debt expense has been recognized Expense recognised during period for bad and doubtful debts for related party transaction Document Financial Statement Error Correction Document Financial Statement Error Correction [Flag] Estimated Allocation Date Six Estimated Allocation Date Six [Member] Estimated Allocation Date Six Settlement Of Contractual Pre-Existing Relationships Settlement Of Contractual Pre-Existing Relationships Settlement Of Contractual Pre-Existing Relationships Restructuring Current restructuring provision Contract Assets Attibutable To Performance Obligations Satisfied In Prior Periods Contract Assets Attibutable To Performance Obligations Satisfied In Prior Periods Contract Assets Attibutable To Performance Obligations Satisfied In Prior Periods Cash and cash equivalents Cash and cash equivalents at the beginning of the period Cash and cash equivalents as of December 31 Cash and cash equivalents Employee Stock Ownership Plan (ESOP) Name [Domain] Employee Stock Ownership Plan (ESOP) Name [Domain] Employee Stock Ownership Plan (ESOP) Name [Domain] Disclosure Of Effect Of Changes In Foreign Exchange Rates [Table] Disclosure Of Effect Of Changes In Foreign Exchange Rates [Table] Disclosure Of Effect Of Changes In Foreign Exchange Rates [Table] Intellectual property rights Intellectual Property Rights [Member] Intellectual Property Rights Solidarity surcharge rate (as a percent) Solidarity Surcharge Rate Solidarity Surcharge Rate Finance Income (Expense) Finance Income (Expense) [Member] Finance Income (Expense) BioNTech Innovative Manufacturing Services GmbH BioNTech Innovative Manufacturing Services GmbH [Member] BioNTech Innovative Manufacturing Services GmbH Summary of Transactions Between Other Related Parties Disclosure of transactions between related parties [text block] Total equity and liabilities Equity and liabilities United States United States UNITED STATES Property, plant and equipment [abstract] Property, plant and equipment [abstract] Accounting Policies, Changes In Accounting Estimates And Errors [Abstract] Accounting Policies, Changes In Accounting Estimates And Errors [Abstract] Accounting Policies, Changes In Accounting Estimates And Errors [Abstract] Business combinations [axis] Business combinations [axis] CureVac Merger B.V. CureVac Merger B.V. [Member] CureVac Merger B.V. Total Provisions Land and buildings Land and buildings [member] Business combinations Business combinations [domain] Acquisitions through business combinations, right-of-use assets Acquisitions through business combinations, right-of-use assets Intellectual property rights, licenses, software and similar rights Concessions, Licenses And Similar Rights [Member] Concessions, Licenses And Similar Rights BioNTech R&D (Austria) GmbH BioNTech R&D (Austria) GmbH [Member] BioNTech R&D (Austria) GmbH CureVac Inc. CureVac Inc. [Member] CureVac Inc. BioNTech 2024 North America Employee Participation Plan - PSUs BioNTech 2024 North America Employee Participation Plan - PSUs [Member] BioNTech 2024 North America Employee Participation Plan - PSUs LTI 2020 program Employee Equity Plan, Long-Term Incentive 2020 Program [Member] Employee Equity Plan, Long-Term Incentive 2020 Program Costs of inventories Cost of inventories recognised as expense during period Product and Service [Domain] Product and Service [Domain] BioNTech BioNTainer Holding GmbH BioNTech BioNTainer Holding GmbH [Member] BioNTech BioNTainer Holding GmbH Treasury shares used for acquisition of business combination Treasury Shares Used For Acquisition Of Business Combination Treasury Shares Used For Acquisition Of Business Combination Transaction price allocated to remaining performance obligations Transaction price allocated to remaining performance obligations National Institutes of Health National Institutes of Health [Member] National Institutes of Health External legal advice services Litigation Costs [Member] Litigation Costs Research and development expense (as a percent) Percentage Of Research And Development Expense Percentage Of Research And Development Expense Non-listed equity investments Non-Listed Equity Investments [Member] Non-Listed Equity Investments Cash outflow for share based payment exercise Cash Outflow For Share Based Payment Arrangement Exercise Cash Outflow For Share Based Payment Arrangement Exercise Inventories Inventories 1 [Member] Inventories 1 thereof allocated and vested but subject to performance and waiting requirements (in shares) Number Of Share Options Allocated And Vested, Subject To Performance And Waiting Requirements In Share-Based Payment Arrangement Number Of Share Options Allocated And Vested, Subject To Performance And Waiting Requirements In Share-Based Payment Arrangement City Area Code City Area Code U.S. dollar United States of America, Dollars General and administrative expense (as a percent) Percentage Of General And Administrative Expense Percentage Of General And Administrative Expense Current and deferred taxes Current And Deferred Tax Expense (Income) Current And Deferred Tax Expense (Income) BioNTech Collaborations GmbH BioNTech Collaborations GmbH [Member] BioNTech Collaborations GmbH CureVac N.V. CureVac N.V. [Member] CureVac N.V. Property, plant and equipment, useful life (in years) Useful life measured as period of time, property, plant and equipment More than 5 years Later than five years [member] Decrease cost of sales Increase (Decrease) Cost Of Sales Increase (Decrease) Cost Of Sales Related Party Disclosures Disclosure of related party [text block] American Depositary Shares, each Representing one ordinary share American Depositary Shares Each Representing One Ordinary Share [Member] American Depositary Shares Each Representing One Ordinary Share Classes of financial assets Classes of financial assets [domain] Impairment Impairment loss recognised in profit or loss, intangible assets and goodwill Impairment loss recognised in profit or loss, intangible assets and goodwill Basis of Preparation Statement of IFRS compliance [text block] Share-based Payment Arrangements [Abstract] Share-based Payment Arrangements [Abstract] Share-based Payment Arrangements [Abstract] Level 3 Level 3 of fair value hierarchy [member] Disclosure of reconciliation of changes in intangible assets and goodwill [table] Disclosure of reconciliation of changes in intangible assets and goodwill [table] FVTPL Fair Value Through Profit Or Loss [Member] Fair Value Through Profit Or Loss Federal corporate income tax (as a percent) Federal Corporate Income Tax Federal Corporate Income Tax Other non-financial assets Total current Other current non-financial assets Interest on lease liabilities Interest expense on lease liabilities Significant Accounting Judgements, Estimates and Assumptions Disclosure of accounting judgements and estimates [text block] Trade and other payables Trade and other payables Events After Reporting Period [Abstract] Events After Reporting Period [Abstract] Events After Reporting Period [Abstract] Goodwill recognised as of acquisition date Goodwill from the acquisition Goodwill recognised as of acquisition date Currency effects functional currency Currency Effects Of Current Contract Liabilities Currency Effects Of Current Contract Liabilities Unobservable inputs [axis] Unobservable inputs [axis] Employee Stock Ownership Plan 2019 Employee Stock Ownership Plan 2019 [Member] Employee Stock Ownership Plan 2019 Auditor Name Auditor Name Audit Information [Abstract] Audit Information Management Board Grant ESOP Management Board Grant ESOP [Member] Management Board Grant ESOP Trade payables and other payables Trade Payables And Other Payables [Member] Trade Payables And Other Payables Disclosure of disaggregation of revenue from contracts with customers [line items] Disclosure of disaggregation of revenue from contracts with customers [line items] Other financial assets Other current financial assets Remaining upfront fees contract liabilities Remaining Upfront Fees Contract Liabilities Remaining Upfront Fees Contract Liabilities Goodwill Goodwill [member] Categories of financial assets [abstract] Categories of financial assets [abstract] Expected life (in years) Option life, share options granted Awards paid at end of month settled Percentage Of American Depository Shares To Ordinary Shares, Awards Settled At End Of Month Percentage Of American Depository Shares To Ordinary Shares, Awards Settled At End Of Month Exchange Rate Used To Determine Fair Value In Business Combination Exchange Rate Used To Determine Fair Value In Business Combination Exchange Rate Used To Determine Fair Value In Business Combination Net cash flows from operating activities Cash flows from (used in) operating activities Finished goods Current finished goods Forfeited (in shares) Forfeited (in shares) Number of other equity instruments forfeited in share-based payment arrangement Disclosure of terms and conditions of share-based payment arrangement [line items] Disclosure of terms and conditions of share-based payment arrangement [line items] Leases [Abstract] Leases 1 [Abstract] Leases 1 Revenue recognition applying the sales-based or usage-based royalty recognition constraint model Sales Based Or Usage Based Royalty Recognition Constraint Model [Member] Sales Based Or Usage Based Royalty Recognition Constraint Model Non-current liabilities Non-current liabilities [abstract] Share-Based Payments Disclosure of share-based payment arrangements [text block] Other financial liabilities Other non-current financial liabilities Other operating income Miscellaneous other operating income thereof: attributable to performance obligations satisfied in prior periods Non-Current Contract Assets Attibutable To Performance Obligations Satisfied In Prior Periods Non-Current Contract Assets Attibutable To Performance Obligations Satisfied In Prior Periods BioNTech 2024 North America Employee Participation Plan - RSUs BioNTech 2024 North America Employee Participation Plan - RSUs [Member] BioNTech 2024 North America Employee Participation Plan - RSUs Document Fiscal Year Focus Document Fiscal Year Focus Liabilities from share-based payment arrangements Liabilities from share-based payment transactions Adjustments to reconcile loss before tax to net cash flows: Adjustments to reconcile profit (loss) [abstract] SOUTH AFRICA SOUTH AFRICA Key management personnel compensation, severance additional payment Key management personnel compensation, Severance Additional Payment Key management personnel compensation, Severance Additional Payment Current Current financial liabilities Decrease in trade and other receivables, contract assets and other assets Adjustments For Decrease (Increase) In Trade Accounts Receivable, Contract Assets And Other Assets Adjustments For Decrease (Increase) In Trade Accounts Receivable, Contract Assets And Other Assets Non-current loans and borrowings Non-Current Loans and Borrowings [Member] Non-Current Loans and Borrowings Key management personnel compensation, consultancy agreement payment Key management personnel compensation, Consultancy Agreement Payment Key management personnel compensation, Consultancy Agreement Payment Other income Other income BioNTech BioNTech [Member] BioNTech Issue costs of equity instruments for business combination Issue Costs Of Equity Instruments For Business Combination Issue Costs Of Equity Instruments For Business Combination Summary of Standards Issued but Not Yet Effective Disclosure of expected impact of initial application of new standards or interpretations [text block] Contractual disputes / settlements Legal proceedings provision Share Repurchase Program Period [Axis] Share Repurchase Program Period [Axis] Share Repurchase Program Period Purchases of various goods and services from entities controlled by ATHOS KG Purchases Of Goods And Service Related Party Transactions Purchases Of Goods And Service Related Party Transactions Other Other Liabilities, Other Other Liabilities, Other Total compensation of key management personnel Key management personnel compensation Estimated Allocation Date Five Estimated Allocation Date Five [Member] Estimated Allocation Date Five Other losses Other finance cost Foreign exchange forward contracts Derivative financial liabilities Change in fair value with decreasing input factor (in millions €) Decrease in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, liabilities Ordinary shares Ordinary shares [member] Total amounts recognized in profit or loss Lease Expenses Recognized In Profit Or Loss Lease Expenses Recognized In Profit Or Loss Effects of dilution from share options (in shares) Dilutive effect of share options on weighted average number of ordinary shares Deductible Temporary Differences, Unused Tax Losses, And Unused Tax Credits Deductible Temporary Differences, Unused Tax Losses, And Unused Tax Credits [Member] Deductible Temporary Differences, Unused Tax Losses, And Unused Tax Credits Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [text block] Earnings per Share Disclosure of earnings per share [text block] Gross carrying amount Gross carrying amount [member] Trade payables and other payables Trade and other current payables Statutory tax rate (as a percent) Applicable tax rate BioNTech 2024 North America Employee Participation Plan BioNTech 2024 North America Employee Participation Plan [Member] BioNTech 2024 North America Employee Participation Plan Inventories Disclosure of inventories [text block] Revenue From Contracts With Customers [Abstract] Revenue From Contracts With Customers [Abstract] Revenue From Contracts With Customers [Abstract] Finance expense excluding foreign exchange differences Adjustments for finance costs Intangible Assets Description of accounting policy for intangible assets and goodwill [text block] Local Phone Number Local Phone Number Less than 1 year Not later than one year [member] Medilink Therapeutics (Suzhou) Co. Ltd., Medilink Therapeutics (Suzhou) Co. Ltd., [Member] Medilink Therapeutics (Suzhou) Co. Ltd., Net employee defined benefit liabilities Net Employee Defined Benefit Liabilities [Member] Net Employee Defined Benefit Liabilities Effect on pre-tax equity Foreign Currency Changes Effect On Pretax Equity Foreign Currency Changes Effect On Pretax Equity BioNTech Switzerland GmbH BioNTech Switzerland GmbH [Member] BioNTech Switzerland GmbH Unvested Unvested [Member] Unvested Losses from financial assets or financial liabilities that are mandatorily measured at fair value through profit or loss Finance Costs, Fair Value Adjustments Of Financial Instruments Measured At Fair Value Finance Costs, Fair Value Adjustments Of Financial Instruments Measured At Fair Value Management Board Grant Management Board Grant [Member] Management Board Grant Intangible assets Identifiable intangible assets recognised as of acquisition date Reclassification from non-current to current Reclassification From Non-Current To Current, Current Contract Assets Reclassification From Non-Current To Current, Current Contract Assets Decrease in inventories Adjustments for decrease (increase) in inventories Disclosure of financial assets [line items] Disclosure of financial assets [line items] Cash paid (fractional shares) Cash transferred Property, plant and equipment [member] Property, plant and equipment [member] European Commission To Collaboration Partner European Commission To Collaboration Partner [Member] European Commission To Collaboration Partner Property, Plant and Equipment Description of accounting policy for property, plant and equipment [text block] Lease liabilities, loans and borrowings Non-current Lease Liabilities, Loans And Borrowings Non-current Lease Liabilities, Loans And Borrowings Total consideration Consideration transferred, acquisition-date fair value Proceeds from loans and borrowings Proceeds from borrowings, classified as financing activities Payments related to lease liabilities Payments of lease liabilities, classified as financing activities Entity Voluntary Filers Entity Voluntary Filers Impairment loss recognised in profit or loss Impairment loss recognised in profit or loss Business Combinations Disclosure of business combinations [text block] Currency effects Increase (decrease) through changes in fair values, liabilities arising from financing activities % equity interest Ownership of ordinary shares in BioNTech (in %) Proportion of ownership interest in subsidiary Investment in Ryvu Ryvu [Member] Ryvu Miscellaneous Miscellaneous [Member] Miscellaneous Option rights vesting period (in years) Option Vesting Period Option Vesting Period Impairment loss for a reduction of future cash flows (as a percent) Percentage Of Impairment Loss For A Reduction Of Future Cash Flows Percentage Of Impairment Loss For A Reduction Of Future Cash Flows Other Non-Financial Assets [Abstract] Other Non-Financial Assets Entity Registrant Name Entity Registrant Name Basic earnings for the period per share (in euros per share) Basic profit for the period per share (in euros per share) Basic earnings (loss) per share Recognition as revenues Decrease through performance obligation being satisfied, contract liabilities Net foreign exchange differences Adjustments for unrealised foreign exchange losses (gains) Exercise price of phantom options granted (in euro per share) Exercise Price, Phantom Options Granted Exercise Price, Phantom Options Granted Liquidity risk Liquidity risk [member] Summary of Accumulated Tax Losses Disclosure Of Accumulated Tax Losses Explanatory [Table Text Block] Disclosure Of Accumulated Tax Losses Explanatory Chief Executive Officer Grant Chief Executive Officer Grant [Member] Chief Executive Officer Grant Weighted average number of ordinary shares outstanding adjusted for the effect of dilution (in shares) Weighted average number of ordinary shares used in calculating diluted earnings per share Duality Biologics (Suzhou) Co. Ltd., Duality Biologics (Suzhou) Co. Ltd., [Member] Duality Biologics (Suzhou) Co. Ltd., Consolidated structured entities [axis] Consolidated structured entities [axis] Classes of intangible assets other than goodwill [domain] Classes of intangible assets other than goodwill [domain] Share-based payment expenses Adjustments for share-based payments Sales and marketing expense (as a percent) Percentage Of Sales And Marketing Expense Percentage Of Sales And Marketing Expense Financial Assets and Financial Liabilities Disclosure of offsetting of financial assets and financial liabilities [text block] Classes of intangible assets and goodwill [axis] Classes of intangible assets and goodwill [axis] Non tax-effective income Tax Effect, Non Tax Effective Income Tax Effect, Non Tax Effective Income InstaDeep Ltd. InstaDeep Ltd. [Member] InstaDeep Ltd. Supervisory Board Supervisory Board [Member] Supervisory Board Inventories [Abstract] Inventories [Abstract] Inventories [Abstract] Liabilities to employees Liabilities For Employee Benefits Liabilities For Employee Benefits Summary of Detailed Information About Intangible Assets Disclosure of reconciliation of changes in intangible assets and goodwill [text block] Non-controlling interests Profit (loss), attributable to non-controlling interests Rest of World Rest of World [Member] Rest of World All Currencies [Domain] All Currencies [Domain] Equity Equity [abstract] LTI Program Employee Equity Plan, Long-Term Incentive Program [Member] Employee Equity Plan, Long-Term Incentive Program Tax-effective equity transaction costs Tax Effective Equity Transaction Costs Tax Effective Equity Transaction Costs Disclosure of disaggregation of revenue from contracts with customers [table] Disclosure of disaggregation of revenue from contracts with customers [table] Disclosure of fair value measurement of assets Disclosure of fair value measurement of assets [text block] BioNTech US Inc. BioNTech US Inc. [Member] BioNTech US Inc. Estimated Allocation Date Three Estimated Allocation Date Three [Member] Estimated Allocation Date Three Monetary assets in U.S. dollar Monetary Assets [Member] Monetary Assets Cash flow projections Cash Flow Projections, Measurement Input [Member] Cash Flow Projections, Measurement Input Fair value of shares transferred Purchase Price, Acquisition-Date Fair Value Purchase Price, Acquisition-Date Fair Value Contract Liabilities Contract Liabilities [Table Text Block] Contract Liabilities BioNTech Manufacturing Marburg GmbH BioNTech Manufacturing Marburg GmbH [Member] BioNTech Manufacturing Marburg GmbH Weighted average fair value Weighted average fair value at measurement date, share options granted Hedging instruments [axis] Hedging instruments [axis] Disclosure Of Income And Expenses [Line Items] Disclosure Of Income And Expenses [Line Items] Disclosure Of Income And Expenses Cash Dividend Description of accounting policy for dividends [text block] Additions Additions other than through business combinations, intangible assets other than goodwill Net gain / (loss) on equity instruments designated at fair value through other comprehensive income Financial assets at fair value through other comprehensive income, category [member] InstaDeep LLC InstaDeep LLC [Member] InstaDeep LLC ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Summary of Significant Unobservable Inputs Used in Fair Value Measurement Disclosure of significant unobservable inputs used in fair value measurement of liabilities [text block] Disclosure of temporary difference, unused tax losses and unused tax credits [table] Disclosure of temporary difference, unused tax losses and unused tax credits [table] Contractual disputes / settlements Contractual Disputes And Settlements [Member] Contractual Disputes And Settlements Total cash outflow for leases Cash outflow for leases Social security costs Social security contributions Increase (decrease) in other operating income (expense) Increase (Decrease) In Other Operating Income (Expense) Increase (Decrease) In Other Operating Income (Expense) Biotheus (Hong Kong) Ltd. Biotheus (Hong Kong) Ltd. [Member] Biotheus (Hong Kong) Ltd. Auditor Firm ID Auditor Firm ID Corporate Information Disclosure Of Corporate Information Explanatory [Text Block] Disclosure Of Corporate Information Explanatory Cash and cash equivalents Cash And Cash Equivalents 1 [Member] Cash And Cash Equivalents 1 Summary of Disaggregation of Revenues from Contracts with Customers Disclosure of disaggregation of revenue from contracts with customers [text block] Income And Expenses By Nature [Domain] Income And Expenses By Nature [Domain] Income And Expenses By Nature [Domain] Financial assets pledged as collateral for liabilities or contingent liabilities Financial assets pledged as collateral for liabilities or contingent liabilities Summary of Shares Repurchase Program Disclosure of Shares Repurchase Program [Table Text Block] Disclosure of Shares Repurchase Program Government grants Adjustments For Movements In Government Grants Adjustments For Movements In Government Grants Recognized in OCI Deferred Tax Expense (Income) Recognised In Other Comprehensive Income Deferred Tax Expense (Income) Recognised In Other Comprehensive Income Number of share options held (in shares) Number Of Share Options Held Number Of Share Options Held Share-Based Payment Arrangements Share-Based Payment Arrangements [Member] Share-Based Payment Arrangements Reclassification from non-current to current Reclassification From Non-Current To Current, Current Contract Liabilities Reclassification From Non-Current To Current, Current Contract Liabilities Total liabilities Liabilities Government Grants Description of accounting policy for government grants [text block] FVTOCI Fair Value Through OCI [Member] Fair Value Through OCI Thereof deferred tax assets Thereof Deferred Tax Assets [Member] Thereof Deferred Tax Assets Summary of Other Non-Financial Liabilities Disclosure Of Detailed Information About Other Non-Financial Liabilities Explanatory [Table Text Block] Disclosure Of Detailed Information About Other Non-Financial Liabilities Explanatory Contingent consideration recognised as of acquisition date Contingent consideration (milestones) Contingent consideration recognised as of acquisition date Disclosure of subsidiaries [table] Disclosure of subsidiaries [table] Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [table] Disclosure of fair value of investments in equity instruments designated at fair value through other comprehensive income [table] Income tax liabilities Current tax liabilities, current Title and Position [Axis] Title and Position [Axis] Increase in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, assets Increase in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, assets Estimated Allocation Date Four Estimated Allocation Date Four [Member] Estimated Allocation Date Four No Trading Symbol Flag No Trading Symbol Flag Money market funds Money Market Funds 1 [Member] Money Market Funds 1 Currency differences Increase (decrease) through net exchange differences, property, plant and equipment Other Non-Financial Assets Disclosure of other assets [text block] Lease liabilities Lease liabilities [member] Lease liabilities, loans and borrowings Current Lease Liabilities, Loans And Borrowings Current Lease Liabilities, Loans And Borrowings Financial Statement Line Items [Axis] Financial Statement Line Items [Axis] Financial Statement Line Items Vesting period of share-based payment arrangement Vesting Period Of Share-Based Payment Arrangement Vesting Period Of Share-Based Payment Arrangement Forfeited (in euros per share) Weighted average exercise price of share options forfeited in share-based payment arrangement BioNTech Rwanda Ltd. BioNTech Rwanda Ltd. [Member] BioNTech Rwanda Ltd. Estimated Allocation Date One Estimated Allocation Date One [Member] Estimated Allocation Date One Summary of Other Operating Income Disclosure Of Other Operating Income Explanatory [Table Text Block] Disclosure Of Other Operating Income Explanatory Expense arising from equity-settled share-based payment arrangements Expense from equity-settled share-based payment transactions Current income taxes Current tax expense (income) Hedging instruments Hedging instruments [domain] Non-adjusting events after reporting period [axis] Non-adjusting events after reporting period [axis] 1 to 5 years Later than one year and not later than five years [member] Equipment, tools and installations Equipment, Tools And Installations [Member] Equipment, Tools And Installations Summary of Standards Applied for the First Time Disclosure of initial application of standards or interpretations [text block] Maximum Top of range [member] Jens Holstein Jens Holstein [Member] Jens Holstein Pfizer Inc. Pfizer Inc [Member] Pfizer Inc Research and development expenses Research and development expenses Research and development expense Settlement Date December 6 2025 Settlement Date December 6 2025 [Member] Settlement Date December 6 2025 Weighted average share price (in euros per share) Weighted average share price Financial Instruments [Abstract] Financial Instruments [Abstract] Financial Instruments [Abstract] Vesting Status Axis [Domain] Vesting Status Axis [Domain] Vesting Status Axis [Domain] Granted under LTI 2020 and LTI-plus program (in euros per share) Weighted average exercise price of other equity instruments granted in share-based payment arrangement NT Security and Services GmbH NT Security and Services GmbH [Member] NT Security and Services GmbH Summary of Lease Liability Included in Interest-Bearing Loans and Borrowings Disclosure Of Detailed Information About Lease Liabilities Explanatory [Table Text Block] Disclosure Of Detailed Information About Lease Liabilities Explanatory Effects from tax losses and tax credits Tax effect of tax losses Foreign exchange differences, net Net foreign exchange gain Remeasurement gain / (loss) on defined benefit plans Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans Trade and other receivables Trade And Other Receivables [Member] Trade And Other Receivables Tax losses / tax credits Unused tax credits [member] Net other comprehensive income / (loss) that will not be reclassified to profit or loss in subsequent periods Other comprehensive income that will not be reclassified to profit or loss, net of tax Other operating expenses Miscellaneous other operating expense Inventories Description of accounting policy for measuring inventories [text block] Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] JPT Peptide Technologies GmbH JPT Peptide Technologies GmbH [Member] JPT Peptide Technologies GmbH Other related parties Other related parties [member] Currency risk Currency risk [member] Impairment losses on financial assets Impairment loss (reversal of impairment loss) recognised in profit or loss Summary of Current and Deferred Tax Expense Disclosure Of Current And Deferred Tax Expense Explanatory [Table Text Block] Disclosure Of Current And Deferred Tax Expense Explanatory Revenues Revenue from contracts with customers Biotheus (Suzhou) Co. Ltd. Biotheus (Suzhou) Co. Ltd. [Member] Biotheus (Suzhou) Co. Ltd. Value Added Tax Receivables Value Added Tax Receivables [Member] Value Added Tax Receivables Post-Offer Subsidiaries Post-Offer Subsidiaries [Member] Post-Offer Subsidiaries Maximum economic benefits of options exercised Maximum Economic Benefits Of Options Exercised Maximum Economic Benefits Of Options Exercised Income And Expenses By Nature [Axis] Income And Expenses By Nature [Axis] Income And Expenses By Nature Decrease in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, assets Decrease in fair value measurement due to change in multiple unobservable inputs to reflect reasonably possible alternative assumptions, assets Deferred expenses Deferred Expense Deferred Expense Deferred tax liabilities Deferred tax liabilities Geographical [Axis] Geographical [Axis] Total assets Assets Recognised As Of Acquisition Date Assets Recognised As Of Acquisition Date Income tax received / (paid), net Income taxes paid (refund), classified as operating activities Other comprehensive loss, net of tax Other comprehensive income (loss) Other comprehensive income Classes of liabilities [axis] Classes of liabilities [axis] Right-of-use assets, useful life (in years) Useful Life Measured As Period Of Time, Right-Of-Use Assets Useful Life Measured As Period Of Time, Right-Of-Use Assets BioNTech 2020 and 2024 Restricted Stock Unit Plans for North American Employees BioNTech 2020 Restricted Stock Unit Plan For North America Employees BioNTech 2020 Restricted Stock Unit Plan For North America Employees [Member] BioNTech 2020 Restricted Stock Unit Plan For North America Employees Treasury shares Treasury shares [member] Share options outstanding Number Of Ordinary Shares Underlying Options [Abstract] Number Of Ordinary Shares Underlying Options Total identifiable net assets at fair value Identifiable assets acquired (liabilities assumed) Liabilities [Roll Forward] Liabilities [Roll Forward] Liabilities Non-tax effective bargain purchase Non Tax Effective Bargain Purchase Non Tax Effective Bargain Purchase Net decrease in cash and cash equivalents Increase (decrease) in cash and cash equivalents before effect of exchange rate changes Types of share-based payment arrangements [axis] Types of share-based payment arrangements [axis] Depreciation, amortization and impairment of property, plant, equipment, intangible assets and right-of-use assets Adjustments for depreciation and amortisation expense Share Options Outstanding [Abstract] Share Options Outstanding [Abstract] Share Options Outstanding Standards Applied for the First Time Disclosure Of Accounting Policy For Initial Application Of Standards Or Interpretations Explanatory [Policy Text Block] Disclosure Of Accounting Policy For Initial Application Of Standards Or Interpretations Explanatory Title of 12(b) Security Title of 12(b) Security Disclosure of subsidiaries [line items] Disclosure of subsidiaries [line items] Summary of Significant Unobservable Inputs (Level 3) Used for Recurring Fair Value Measurements and the Effect of the Measurements Disclosure of fair value measurement of liabilities [text block] Issueance of share capital Issue of equity Exchange Ratio In Business Combination Exchange Ratio In Business Combination Exchange Ratio In Business Combination France and Rest of World France and Rest of World [Member] France and Rest of World Attribution of expenses by nature to their function [domain] Attribution of expenses by nature to their function [domain] Treasury Shares Description of accounting policy for treasury shares [text block] LTI 2024 program - PRSUs Employee Equity Plan, Long-Term Incentive 2024 Program, PRSUs [Member] Employee Equity Plan, Long-Term Incentive 2024 Program, PRSUs Total liabilities Liabilities Recognised As Of Acquisition Date Liabilities Recognised As Of Acquisition Date Thereof deferred tax liability Thereof Deferred Tax Liability [Member] Thereof Deferred Tax Liability Subsidiaries [domain] Subsidiaries [domain] Repayment of loans and borrowings Repayments of borrowings, classified as financing activities Raw materials and supplies Current raw materials and current production supplies Share Capital, Reserves and Other Equity Interest [Abstract] Share Capital, Reserves and Other Equity Interest [Abstract] Share Capital, Reserves and Other Equity Interest [Abstract] Current Current financial assets Growth rate used to extrapolate cash flow projections (as a percent) Growth rate used to extrapolate cash flow projections Exercised (in shares) Number Of Ordinary Shares Underlying Options Exercised In Share-based Payment Arrangement Number Of Ordinary Shares Underlying Options Exercised In Share-based Payment Arrangement Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items] Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items] Disclosure Of Effect Of Changes In Foreign Exchange Rates [Line Items] Contingent liabilities and other financial commitments Disclosure of commitments and contingent liabilities [text block] Number of share options outstanding, amount of shares With expiration dates (in shares) Number Of Share Options Outstanding, Amount Of Shares With Expiration Dates Number Of Share Options Outstanding, Amount Of Shares With Expiration Dates Recognition as revenues Non-Current Contract Liabilites Recognized As Revenue Non-Current Contract Liabilites Recognized As Revenue Summary of Property, Plant and Equipment Disclosure of detailed information about property, plant and equipment [text block] Classes of intangible assets and goodwill Classes of intangible assets and goodwill [domain] Licenses Licences [member] Treasury shares used for acquisition of business combination Share Repurchase Program, Repurchased During Period, Value Share Repurchase Program, Repurchased During Period, Value Summary of Estimated Useful Lives of the Assets or Shorter Lease Term Disclosure Of Right-Of-Use Assets Estimated Useful Lives Explanatory [Table Text Block] Disclosure Of Right-Of-Use Assets Estimated Useful Lives Explanatory Net cash flows used in investing activities Cash flows from (used in) investing activities Vesting Status Axis [Axis] Vesting Status Axis [Axis] Vesting Status Axis Recognition as revenues Current Contract Liabilites Recognized As Revenue Current Contract Liabilites Recognized As Revenue Disclosure of detailed information about intangible assets [line items] Disclosure of detailed information about intangible assets [line items] Non-current Non-current financial assets Total Employee benefits expense Biotheus Inc., Biotheus Inc., [Member] Biotheus Inc., Reclassification to trade accounts receivables Reclassification Io Trade Accounts Receivables, Current Contract Assets Reclassification Io Trade Accounts Receivables, Current Contract Assets Summary of Carrying Amount of Monetary Assets Disclosure Of Foreign Currency Risk Explanatory [Table Text Block] Disclosure Of Foreign Currency Risk Explanatory Employee Stock Ownership Plan Employee Stock Ownership Plan [Member] Employee Stock Ownership Plan Financial Instruments Description of accounting policy for financial instruments [text block] Interests In Other Entities [Abstract] Interests In Other Entities [Abstract] Interests In Other Entities [Abstract] Total current assets Current assets Unrealized (gain) / loss on derivative instruments at fair value through profit or loss Gains (losses) on financial liabilities at fair value through profit or loss Total Contractual capital commitments Total for all subsidiaries Total for all subsidiaries [member] Recognized in P&L Deferred tax expense (income) recognised in profit or loss Obligation to issue share capital Equity To Be Issued Equity To Be Issued Goods and services transferred over time Goods or services transferred over time [member] Net change in fair value Gains (losses) recognised in profit or loss including exchange differences, fair value measurement, liabilities Related Party [Abstract] Related Party [Abstract] Related Party [Abstract] Government Grants Received Government Grants Received Government Grants Received Number of ADSs purchased (in shares) Share Repurchase Program, Number Of American depositary Shares (ADS) Purchased Share Repurchase Program, Number Of American depositary Shares (ADS) Purchased Types of risks [axis] Types of risks [axis] Total Cash And Cash Equivalent Cash And Cash Equivalent Bonds Bonds 1 [Member] Bonds 1 Disclosure of transactions between related parties [table] Disclosure of transactions between related parties [table] Reclassification to trade accounts receivables Reclassification Io Trade Accounts Receivables, Non-Current Contract Assets Reclassification Io Trade Accounts Receivables, Non-Current Contract Assets Depreciation Depreciation, property, plant and equipment Summary of Effect of Changes in Foreign Exchange Rates Disclosure Of Effect Of Changes In Foreign Exchange Rates Explanatory [Table Text Block] Disclosure Of Effect Of Changes In Foreign Exchange Rates Explanatory Income tax assets Current tax assets, current Attribution of expenses by nature to their function [axis] Attribution of expenses by nature to their function [axis] thereof fair value of shares for the back-end measures Purchase Price, Acquisition-Date Fair Value, Back-End Measures Purchase Price, Acquisition-Date Fair Value, Back-End Measures Expected volatility Expected volatility, share options granted Property, Plant and Equipment Disclosure of property, plant and equipment [text block] BioNTech Delivery Technologies (US), LLC BioNTech Delivery Technologies (US), LLC [Member] BioNTech Delivery Technologies (US), LLC LTI 2022 program Employee Equity Plan, Long-Term Incentive 2022 Program [Member] Employee Equity Plan, Long-Term Incentive 2022 Program Share Repurchase Program 2023 Share Repurchase Program 2023 [Member] Share Repurchase Program 2023 Amendment Flag Amendment Flag Components of equity Components of equity [domain] Disclosure Of Financial Assets And Liabilities [Table] Disclosure Of Financial Assets And Liabilities [Table] Disclosure Of Financial Assets And Liabilities [Table] Total Purchases From Related Party Transactions Purchases From Related Party Transactions Monetary liabilities and provisions in U.S. dollar Monetary Liability And Provisions [Member] Monetary Liability And Provisions Exercised (in euros per share) Weighted Average Exercise Price Of Share Options Exercised In Share-Based Payment Arrangement Weighted Average Exercise Price Of Share Options Exercised In Share-Based Payment Arrangement New leases and disposals Increase through new leases, liabilities arising from financing activities Temporary difference, unused tax losses and unused tax credits [axis] Temporary difference, unused tax losses and unused tax credits [axis] Range [domain] Range [domain] (Gain) / Loss on disposal of property, plant and equipment Adjustments for gain (loss) on disposals, property, plant and equipment Fringe benefits Key Management Personnel Compensation, Fringe Benefits Key Management Personnel Compensation, Fringe Benefits thereof vested (in euros per share) Weighted Average Exercise Price Of Share Options Vested In Share-Based Payment Arrangement Weighted Average Exercise Price Of Share Options Vested In Share-Based Payment Arrangement Settlement Date December 11 2025 Settlement Date December 11 2025 [Member] Settlement Date December 11 2025 Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine [Member] Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine Amounts included in contract liabilities at the beginning of the year Revenue that was included in contract liability balance at beginning of period Fee expense from financial assets and financial liabilities that are not subsequently measured at fair value through profit or loss Finance Costs, Fair Value Adjustments Of Financial Instruments Measured At Amortized Cost Without Expected Credit Losses Finance Costs, Fair Value Adjustments Of Financial Instruments Measured At Amortized Cost Without Expected Credit Losses Non-current Non-current financial liabilities Cash outflow Expense from share-based payment transactions Other additions Increase (Decrease) In Current Contract Liabilities Increase (Decrease) In Current Contract Liabilities Current versus Non-Current Classifications Description Of Accounting Policy For Assets And Liabilities Explanatory [Policy Text Block] Description Of Accounting Policy For Assets And Liabilities Explanatory Amortization Accumulated Depreciation, Amortisation And Impairment Accumulated Depreciation, Amortisation And Impairment Additional provisions, other provisions Additional provisions, other provisions Address Type [Domain] Address Type [Domain] Issuance of share capital, net of transaction costs Issuance Of Share Capital Issuance Of Share Capital Other non-financial liabilities Total non-current Other non-current non-financial liabilities Cost of sales (as a percent) Percentage Of Cost Of Sales Percentage Of Cost Of Sales Current Current lease liabilities Income Taxes [Abstract] Income Taxes [Abstract] Income Taxes [Abstract] Ryan Richardson Ryan Richardson [Member] Ryan Richardson Reclassification from non-current to current Reclassification From Non-Current To Current, Non-Current Contract Assets Reclassification From Non-Current To Current, Non-Current Contract Assets Currency [Axis] Currency [Axis] Diluted earnings for the period per share (in euros per share) Diluted profit for the period per share (in euros per share) Diluted earnings (loss) per share Maturity Maturity [domain] CureVac Netherlands B.V. CureVac Netherlands B.V. [Member] CureVac Netherlands B.V. Summary of Information about Subsidiaries Disclosure of subsidiaries [text block] Effect on profit / (loss) before tax Foreign Currency Changes Effect On Loss, Before Tax Foreign Currency Changes Effect On Loss, Before Tax Disclosure of terms and conditions of share-based payment arrangement [table] Disclosure of terms and conditions of share-based payment arrangement [table] Bank Deposits Bank Deposits [Member] Bank Deposits State income tax with average rate (as a percent) Effective tax rate Average effective tax rate Disclosure of reconciliation of liabilities arising from financing activities [table] Disclosure of reconciliation of liabilities arising from financing activities [table] Vehicles Vehicles [member] Settlement Date June 3 2025 Settlement Date June 3 2025 [Member] Settlement Date June 3 2025 Summary of Income and Share Data Used in the Basic and Diluted EPS Calculations Earnings per share [text block] BioNTech Turkey Tıbbi Ürünler Ve Klinik Araştirma Ticaret Anonim Şirketi BioNTech Turkey Tıbbi Ürünler Ve Klinik Araştirma Ticaret Anonim Şirketi [Member] BioNTech Turkey Tıbbi Ürünler Ve Klinik Araştirma Ticaret Anonim Şirketi Categories of financial liabilities [abstract] Categories of financial liabilities [abstract] Counterparty Name [Axis] Counterparty Name [Axis] Liabilities from wage taxes and social securities expenses Liabilities From Wage Taxes And Social Securities Expenses Liabilities From Wage Taxes And Social Securities Expenses OncoC4 Inc. OncoC4 Inc. [Member] OncoC4 Inc. UPenn UPenn [Member] UPenn Disclosure of detailed information about property, plant and equipment [table] Disclosure of detailed information about property, plant and equipment [table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code